Table 2 LL-37–derived peptides are more effective against S. aureus and P. aeruginosa than (pre-)clinical phase peptides.

Bactericidal activity (LC99.9) in PBS and in PBS with 50% human plasma against S. aureus JAR060131 and P. aeruginosa PAO1. Results are medians (and ranges) of three to four independent experiments. If no range is indicated, then LC99.9 values were identical in all experiments.

PeptideDevelopment phaseLC99.9 (μM)
S. aureusP. aeruginosa
PBS50% plasmaPBS50% plasma
Ci MAM-A24Preclinical6.451.2(25.6–51.2)4.8(1.6–6.4)51.2
CZEN-002IIb>102.4>102.4>102.4>102.4
DPK060II>102.4>102.4>102.4(102.4–>102.4)>102.4
GhrelinII>102.4>102.4>102.4>102.4
HB1345Preclinical51.2(25.6–102.4)>102.451.2(25.6–102.4)>102.4
Hepcidin-25Preclinical>102.4>102.4>102.4>102.4
hLF1-11I/II102.4>102.4>102.4(51.2–>102.4)>102.4
IsegananIII3.2(3.2–6.4)12.8(6.4–12.8)2.4(0.8–6.4)51.2(51.2–102.4)
KABT-AMPPreclinical1.625.6(12.8–25.6)1.625.6(12.8–25.6)
OmigananIII51.2>102.46.4(6.4–12.8)>102.4
OP-145I/II1.6(1.6–3.2)>102.43.2(0.8–3.2)>102.4
PexigananIII12.8(6.4–12.8)25.61.6(0.8–1.6)6.4(6.4–25.6)
PlectasinPreclinical>102.4>102.4>102.4>102.4
POL7001Preclinical>102.4>102.451.2(51.2–>102.4)>102.4
S-ThanatinPreclinical>102.4(102.4–>102.4)>102.4102.4>102.4
XOMA-629II>102.4>102.4>102.4>102.4
LL-371.6(1.6–6.4)>102.43.2(1.6–3.2)>102.4
SAAP-1451.6(0.8–1.6)12.8(12.8–25.6)1.6(0.8–1.6)25.6(12.8–25.6)
SAAP-1481.612.8(12.8–25.6)1.612.8(6.4–12.8)
SAAP-1591.6(1.6–3.2)12.81.6(1.6–3.2)12.8(6.4–12.8)
SAAP-2760.86.4(6.4–12.8)0.8(0.8–1.6)51.2